 Inclusion Criteria: - Subjects diagnosed with RA as determined by American College of Rheumatology ACR criteria with a disease duration of at least 24 weeks prior to enrollment - Active RA at screening as defined by EITHER: 1 At least 6 swollen joints using a 66 joint count and at least 6 tender joints using a 68 joint count OR 2 4 non-hand joints and at least 1 of the following: Morning stiffness of at least 45 minutes; CRP greater than 1.5 mgdL 15.0 mgL; ESR greater than 28 mmh; DAS28 greater than 3.2 - Subjects must have failed an adequate trial of at least 3 disease-modifying antirheumatic drugs DMARDS alone or in combination one of which must be MTX and have been on the same treatment and doses for 4 weeks prior to enrollment i.e., an adequate trial is defined as 12 weeks unless limited by toxicity or intolerance - Subjects doses of nonsteroidal antiinflammatory drugs NSAIDs and oral corticosteroids less than or equal to 10 mgday of prednisone or equivalent must have been kept stable for 4 weeks prior to enrollment. 